Search

Displaying results 611 - 620 of 2959 in total
  1. Drug

    Pravastatin

    go.drugbank.com/drugs/DB00175
    ApprovedInvestigational

    .; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991.

    Products: Nra-pravastatin, PRAVASTATINA EG
  2. Drug

    Lacosamide

    go.drugbank.com/drugs/DB06218
    ApprovedInvestigational

    [A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008.

    Products: LACOSAMIDE EG, Nra-lacosamide
  3. Drug

    Dalbavancin

    go.drugbank.com/drugs/DB06219
    ApprovedInvestigational

    Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]. … Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072

  4. Drug

    Iodine povacrylex

    go.drugbank.com/drugs/DB09537
    Approved

    DuraPrep solution is indicated for use as a patient preoperative skin preparation, for the preparation of the skin prior to surgery and to help reduce bacteria that can potentially cause skin infection

  5. Drug

    Tolterodine

    go.drugbank.com/drugs/DB01036
    ApprovedInvestigational

    Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.

    Products: Mylan-tolterodine ER
  6. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered si...

  7. Drug

    Cefiderocol

    go.drugbank.com/drugs/DB14879
    ApprovedInvestigational

    Cefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. … [FDA Label] Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels.

  8. Drug

    Diamorphine

    go.drugbank.com/drugs/DB01452
    ApprovedIllicit

    (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs.

  9. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic

  10. Drug

    Calcium

    go.drugbank.com/drugs/DB01373
    ApprovedInvestigationalNutraceutical

    Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium.

    Mixtures: O-Cal FA multivitamin, Cavan-EC SOD DHAProducts: Tall G U